1st Annual European Healthcare Impact Summit

Nitinotes Ltd. is an early commercial-stage medical device company advancing endoluminal innovation for obesity care. Its flagship platform, EndoZip™, is the first fully automated, single-operator suturing system designed specifically for endoscopic sleeve gastroplasty (ESG).

Brainomix is a global pioneer in AI medical imaging, enabling precision medicine for better treatment decisions in stroke and lung fibrosis. Its flagship product, Brainomix 360 Stroke, is the world's first fully automated AI-imaging platform, designed for acute stroke assessment at all points of the patient pathway, facilitating more confident treatment and transfer decisions for patients in all hospitals, regardless of local resources or expertise. Brainomix 360 e-Lung is an FDA-cleared, AI-powered imaging software platform that automatically identifies and quantifies features on CT lung scans enabling clinicians to more easily identify changes over multiple scan timepoints. Founded as a spinout from the University of Oxford, Brainomix has offices in the UK, Ireland and the USA, and operations in more than 20 countries.

Green Bone Ortho: Core Overview

1. Technology & Production: Green Bone Ortho develops a patented Biomimetic 3D Matrix for Bone Tissue Regeneration, derived from natural wood structures (primarily rattan). Through a multi-step chemical pyrolysis and biotransformation process, wood is converted into 3D porous bone-like scaffold made of Biomimetic Apatite: hydroxyapatite and Beta-tricalcium phosphate ionically doped with Magnesium, Strontium, and Carbonate ions, similar to young bone. The scaffold features hierarchical 3D interconnected porosity matching human bone structure, offering high mechanical strength, load-bearing capacity, and rapid vascularization/osteointegration.

2. Patent Portfolio: The core intellectual property centers on the chemical transformation process converting cellular wood structures into inorganic hydroxyapatite matrix scaffolds. The patent portfolio covers international territories (EU, US, Japan, Asia), protecting both the specific biotransformation manufacturing process and the resulting structural material for orthopedic and trauma applications.

3. Regulatory Status: Green Bone Ortho’s implants are classified as high-risk medical devices. In the European Union, they fall under Regulation (EU) 2017/745 (MDR) as Class III medical devices, requiring CE mark approval supported by rigorous clinical evidence. In the US, regulatory clearance pathways target the FDA 510(k).

4. Commercial Landscape: Operating in the global orthopedic biomaterials market, Green Bone targets major bone defects caused by severe trauma, non-union fractures, and oncological resections. The primary value proposition is replacing autologous bone grafts (harvested from the patient) and synthetic alternatives by providing superior structural support and natural remodeling. The commercialization strategy focuses on partnerships with orthopedic distribution networks, clinical key opinion leaders, and hospital procurement channels.

5. Disruptive Innovation: Green Bone Technology platform drives disruptive innovation across three key pillars: a) preventing implant infections via antibacterial nanostructures and local drug delivery, b) enabling targeted local oncological therapies for bone tumors, c) stimulating systemic osteogenesis to combat osteoporosis and microgravity-induced bone loss in space medicine.

hema.to is a Munich-based AI healthtech company building AI-supported software for automated flow cytometry analysis. Its cloud platform enables laboratories to go from raw data to standardized, reproducible results and reports within seconds. Designed to integrate seamlessly into all existing laboratory workflows, hema.to's product helps laboratories increase efficiency and scale case volumes without additional operational overhead.

iniuva. AI-powered orphan drug development.

iniuva is a Hamburg-based biotech. We develop Pharmacological Chaperones: small molecules that correct protein misfolding at its source, the underlying mechanism in roughly two thirds of patients with a genetic disease, some 34 million people in the EU and USA.

Our platform iniuvaVIU® answers that need: it predicts not just the structure of a misfolded protein but its function, so we design better drug candidates and move from discovery to IND in months rather than years. Because misfolding carries across many indications, the approach is not tied to a single therapeutic area.

Our B2B model fuels biopharma pipelines with de-risked, discovery-to-clinical-stage drug candidates for underserved markets.

We enable precision medicine!

LIMAA develops a fully automated tissue preserving end-to-end histopathology platform for clinical use. We are looking for new partnerships in companion diagnostics based on either volumetric image information or downstream genomics.

NGScopes: Lightweight Through-the-Scope Robotics for Endoscopy

Medical & Market Need: Indications for minimally invasive endoscopic interventions are expanding, but instrument technology has not kept pace. Today's endoscopic instruments are passive tools, rigidly linked to the physician's hand movements outside the body, limiting precision and confining the most advanced procedures to a small number of experts. Heavyweight, expensive endoscopy robots promise more control but reach only a fraction of the ~200 million endoscopies performed each year, requiring significant infrastructure and workflow changes.

Solution: NGScopes builds a robotic instrument platform designed for maximum adoption: compatible with standard endoscopes already in clinical use, a seamless fit into the single-operator workflow, and requiring minimal capital investment. The system consists of a reusable base station and single-use kits containing the instrument and handpiece, scaling from our endoscopic resection knife MVP to steerable snares, needles, bronchoscopy probes, and cholangioscopes.

Stage: NGScopes is a German preclinical-stage startup raising its first financing round. A fully functional prototype, including its first instrument application (an electrosurgical ESD knife), has been validated in ex-vivo animal studies with key opinion leaders.

Business Model: Operating in the endoscopy instruments and accessories market, NGScopes is defining the category of through-the-scope robotics. Revenue comes from high-margin, single-use consumables within existing reimbursement pathways. A limited launch is planned for 2030 (US) and 2031 (EU), starting with GI endoscopy and expanding into pulmonary, hepatobiliary, and urological endoscopy.

Traction: Founded by engineers and endoscopists with close ties to the clinical community, NGScopes has presented at endoscopy conferences in Europe, South Korea, and Japan, and has drawn interest from strategics, including one signed letter of intent.

Ask: NGScopes is raising a $2.0 million first financing round to reach design freeze, prepare for FDA submission under the 510(k) pathway, and expand its key opinion leader network in the US.